Overview
- A Northwestern Medicine study published Wednesday in JAMA reported 100% one-year survival for 17 carefully selected stage 4 lung cancer patients who received lung transplants versus about 41% for similar patients treated with medical therapy alone.
- The study drew on the DREAM registry and analyzed 404 adults treated from September 2021 through June 2025, including 98 patients with lung-only stage 4 disease of whom 17 underwent transplantation and roughly 81 received medical care only due partly to logistical or financial barriers.
- Transplant candidates met strict rules: cancer verified as confined to the lungs, failure of standard systemic therapies such as chemotherapy or immunotherapy, and severe, life‑limiting lung damage that made respiratory failure the immediate risk.
- Authors report not only longer survival but meaningful quality-of-life gains for some recipients, including cases rescued from imminent withdrawal of care, though four transplant patients showed disease progression within the study follow-up period.
- Clinicians and editors note key limits: this is a single-center, observational registry with a small, highly selected transplant group, so the findings prompt urgent calls for larger, multicenter trials, longer follow-up, and careful review of organ-allocation and eligibility policies.